Small Molecule IVD

23rd July 2019
Aptamer based ‘gain of signal’ assay for small molecule detection

Detecting small molecules represents a challenge for In vitro diagnostics (IVD) due to sensitivity and specificity limits of many detection methods. Our specially designed displacement approach allows us to select aptamers that can readily be used in various IVD and point of care (POC) […]

Novel gain of signal approach for small molecule detection

17th July 2019
Small molecules present an ongoing challenge for antibody production and detection. Development of biosensors for the detection of small molecules is difficult due to the lack of suitable antibodies and the relatively small signals. Tools to detect and quantify them are therefore in high demand.

At Aptamer Group we select aptamers that bind to […]

Small molecule detection made easier using Fluorescence Anisotropy technique

9th July 2019
Traditionally, immuno-fluorescence polarization-based assays are used to detect small molecules by using antibodies and fluorescently labelled small-molecules. However, the assays do meet limitations such as complex antibody preparation, cost, and most importantly stability. Also the preparation of fluorescently labelled small molecules is challenging. The use of aptamers overcomes the limitations and brings new […]

Small molecules detection with aptamer based BLI and ELISA-like assays

2nd July 2019
Detecting and quantifying small molecule analytes can be difficult. Our specially designed displacement approach allows us to select aptamers which can directly be used in various biosensor platforms for the detection of small molecules. Binding of the aptamer to the analyte gives a ‘signal amplification’ effect which can be used as a basis for small […]

  • An Aptamer Group robot performing aptamer selection.

Our Small Moleule Approach

25th June 2019
Small molecule targets (such as antibiotics, many drugs, toxins, food additives etc) are often perceived as difficult targets to obtain a suitable affinity ligand. They represent a challenge for traditional aptamer selection approaches which rely on immobilisation of the target molecule for efficient partitioning. Modification of the small molecule to facilitate immobilisation often […]

Literature review: Rapid detection of Kanamycin antibiotic in complex food matrix

18th June 2019
Kanamycin is an aminoglycoside antibiotic isolated from Streptomyces kanamyceticus and is widely used to treat various infectious diseases in humans and animals. However, like other aminoglycoside antibiotics, kanamycin exhibits comparatively narrow safety margin as high doses can cause ototoxicity, nephrotoxicity and allergic reactions.

The current methods used for analysis for detecting kanamycin levels in […]

The Stability of Aptamers

5th June 2019
One of the key benefits to using aptamers instead of antibodies is how you store and use the reagent. Over this past 60 years the stability of oligonucleotides has been rigorously studied and well defined.

Most provides of synthetic oligonucleotides recommend storing the suspended DNA at in a neutral buffer, free from divalent metal […]

Aptamers for siRNA delivery

15th May 2019
siRNA’s are functional double stranded RNA molecules which can be used to control gene expression by targeting a messenger RNA and promoting its degradation.  One of the challenges in the therapeutic application of siRNA’s is targeting and delivery of the siRNA, to the cell / tissue of interest. Various adjuvants have been tested […]

Literature Review: Distinguishing glycosylation patterns in proteins for the early detection of cancer.

7th May 2019
Glycosylation is a post-translational modification where a carbohydrate is added to a protein. Glycosylation of proteins serves a number of functions in a cell, including: improve protein folding, forming lipid anchors and cell-to-cell adhesion. While glycosylation of a protein can be vital for its function, any changes in the position or number of […]

Aptamer Therapeutics and Cancer Research UK announce partnership for drug development programme

30th April 2019
Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester and Cancer Research UK. The project will explore the potential of aptamers as […]